- Treffer 1 von 1
Sodium glucose cotransporter 1 ligand BLF501 as a novel tool for management of gastrointestinal mucositis
Zitieren Sie bitte immer diese URN: urn:nbn:de:bvb:20-opus-117352
- Background: Recent studies demonstrated that engagement of sodium glucose transporter 1 (SGLT-1) by orally administered D-glucose protects the intestinal mucosa from lipopolysaccharide (LPS)-induced injury. We tested whether SGLT-1 engagement might protect the intestinal mucosa from doxorubicin (DXR)- and 5-fluorouracil (5-FU)-induced injury in animal models mimicking acute or chronic mucositis. Methods: Mice were treated intraperitoneally with DXR, alone or in combination with 5-FU, and orally with BLF501, a glucose-derived syntheticBackground: Recent studies demonstrated that engagement of sodium glucose transporter 1 (SGLT-1) by orally administered D-glucose protects the intestinal mucosa from lipopolysaccharide (LPS)-induced injury. We tested whether SGLT-1 engagement might protect the intestinal mucosa from doxorubicin (DXR)- and 5-fluorouracil (5-FU)-induced injury in animal models mimicking acute or chronic mucositis. Methods: Mice were treated intraperitoneally with DXR, alone or in combination with 5-FU, and orally with BLF501, a glucose-derived synthetic compound with high affinity for SGLT-1. Intestinal mucosal epithelium integrity was assessed by histological analysis, cellular proliferation assays, real-time PCR gene expression assays and Western blot assays. Student's t-test (paired two-tailed) and X-2 analyses were used for comparisons between groups. Differences were considered significant at p < 0.05. Results: BLF501 administration in mice treated with DXR and/or 5-FU decreased the injuries to the mucosa in terms of epithelial integrity and cellular proliferative ability. Co-treatment with BLF501 led to a normal expression and distribution of both zonula occludens-1 (ZO-1) and beta-catenin, which were underexpressed after treatment with either chemotherapeutic agent alone. BLF501 administration also restored normal expression of caspase-3 and ezrin/radixin/moesin (ERM), which were overexpressed after treatment with DXR and 5-FU. In SGLT1-/- mice, BLF501 had no detectable effects. BLF501 administration in wild-type mice with growing A431 tumors did not modify antitumor activity of DXR. Conclusions: BLF501-induced protection of the intestinal mucosa is a promising novel therapeutic approach to reducing the severity of chemotherapy-induced mucositis.…
Autor(en): | Diego Cardani, Claudia Sardi, Barbara La Ferla, Guiseppe D'Orazio, Michele Sommariva, Fabrizio Marcucci, Daniela Olivero, Elda Tagliabue, Hermann Koepsell, Francesco Nicotra, Andrea Balsari, Christiano Rumio |
---|---|
URN: | urn:nbn:de:bvb:20-opus-117352 |
Dokumentart: | Artikel / Aufsatz in einer Zeitschrift |
Institute der Universität: | Fakultät für Biologie / Julius-von-Sachs-Institut für Biowissenschaften |
Sprache der Veröffentlichung: | Englisch |
Titel des übergeordneten Werkes / der Zeitschrift (Englisch): | Molecular Cancer |
ISSN: | 1476-4598 |
Erscheinungsjahr: | 2014 |
Band / Jahrgang: | 13 |
Heft / Ausgabe: | 23 |
Originalveröffentlichung / Quelle: | Molecular Cancer 2014 13:23. doi:10.1186/1476-4598-13-23 |
DOI: | https://doi.org/10.1186/1476-4598-13-23 |
PubMed-ID: | https://pubmed.ncbi.nlm.nih.gov/24495286 |
Allgemeine fachliche Zuordnung (DDC-Klassifikation): | 5 Naturwissenschaften und Mathematik / 57 Biowissenschaften; Biologie / 570 Biowissenschaften; Biologie |
Freie Schlagwort(e): | SGLT-1; apoptosis; cancer; chemotherapy; clinical practice guidelines; doxorubicin; epithelial cells; gastrointestinal mucositis; gene-expression; inflammation; intestinal mucositis; oral mucositis; prevention; synthetic D-glucose analogy |
Datum der Freischaltung: | 18.08.2015 |
Lizenz (Deutsch): | CC BY: Creative-Commons-Lizenz: Namensnennung |